Bottom Line: Limits for BOC
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.APPARENTLY grim news yesterday from those harbingers of gloom, BOC, was heralded by a 5 per cent share price rise. But tales of hefty cost-cutting with an identifiable pay-off were precisely what the market wanted to hear.
The medium-term outlook for the group is far from rosy. Continental Europe and Japan are laid low by recession while the US and UK have only just come unsteadily off the drip-feed. BOC has also been hit by the US patent expiry of its anaesthetic, Forane.
There are problems of management succession, too. Pat Rich, until a month ago chairman and chief executive, is to retire in April. With Pat Dyer, chief executive, also in his sixties, BOC has left it a bit late to groom its next top team. The shares, at 699p, offer an above-average yield of about 4.4 per cent but limited potential.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments